137 completed, 30 terminated, 27 recruiting, 20 active not recruiting. 249 Phase 1, 106 Phase 2.
Follow Sirolimus: new trials by email Literature Review of Sirolimus trials Research Report on Sirolimus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage Sirolimus (Rapamune®) - Post-hemorrhagic Hydrocephalus (PHH) | Phase 1 / Phase 2 | Not yet recruiting | Massachusetts General Hospital | 15 | 2027-01-01 | 2026-06-25 |
| Effects of Sirolimus on Asymptomatic ApoE4 Carriers Sirolimus (rapamycin), Placebo - Genetic Predisposition to Disease, Healthy Volunteer | Phase 1 | Recruiting | University of Missouri-Columbia | 225 | 2026-12-01 | 2026-10-05 |
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma Mirdametinib, Sirolimus - Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 54 | 2026-11-23 | 2026-11-18 |
| A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE) FMD1 (LNT22-017-1), Rapamycin, Placebo - Cerebral Blood Flow, APOE 4 | Phase 1 / Phase 2 | Not yet recruiting | Cedars-Sinai Medical Center | 60 | 2026-11-01 | 2026-09-16 |
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-11-01 | 2026-11-10 |
| A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma UB-VV500, Rapamycin (sirolimus) - Multiple Myeloma in Relapse, Multiple Myeloma (MM) | Phase 1 | Recruiting | Umoja Biopharma | 100 | 2026-11-01 | 2026-11-13 |
| Low-Dose Sirolimus for the Treatment of RUNX1 Familial Platelet Disorder Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Familial Platelet Disorder With Associated Myeloid Malignancy | Phase 1 | Recruiting | OHSU Knight Cancer Institute | 6 | 2026-10-05 | 2026-10-13 |
| Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. Dinutuximab beta, Sirolimus and Irinotecan - Osteosarcomas, Bone Cancer | Phase 1 / Phase 2 | Not yet recruiting | University Hospital, Strasbourg, France | 89 | 2026-10-01 | 2026-10-01 |
| Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI Sirolimus, Ruxolitinib, MMF - Acute Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Not yet recruiting | Peking University People's Hospital | 40 | 2026-10-01 | 2026-09-09 |
| Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma Domatinostat, Sirolimus - Sarcoma, Osteosarcoma | Phase 1 / Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 74 | 2026-07-15 | 2026-09-03 |
| Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma Sirolimus, Teclistamab, Talquetamb - Multiple Myeloma | Phase 1 | Recruiting | Christopher Strouse | 10 | 2026-06-01 | 2026-06-04 |
| MTOR Inhibitors in Older Adults Sirolimus 0.5 Mg Oral Tablet, Sirolimus 1Mg Oral Tablet, Sirolimus 2 MG Oral Tablet - Aging | Phase 1 / Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 60 | 2026-05-11 | 2026-06-25 |
| Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators ASP2957, Methylprednisolone, Prednisolone - X-Linked Myotubular Myopathy | Phase 1 / Phase 2 | Recruiting | Astellas Gene Therapies | 9 | 2025-12-15 | 2026-11-09 |
| Matched Related and Unrelated Donor Stem Cell Transplantation for Severe Combined Immune Deficiency (SCID): Busulfan-based Conditioning With h-ATG, Radiation, and Sirolimus Sirolimus, Busulfan, Horse -Anti-thymocyte - Severe Combined Immune Deficiency (SCID) | Phase 1 / Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-11-26 | 2025-12-01 | |
| Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL), Fludarabine, Cyclophosphamide - Hematologic Malignancies, Hematologic Neoplasms | Phase 1 | Recruiting | National Cancer Institute (NCI) | 155 | 2025-11-14 | 2026-10-16 |
| A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors sirolimus (albumin-bound), DP303c, SYS6043 - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 444 | 2025-11-13 | 2025-11-28 |
| Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome Urbagen gene addition therapy, Sirolimus, Methylprednisolone (Corticosteroid) - CTNNB1 Neurodevelopmental Syndrome | Phase 1 / Phase 2 | Recruiting | CTNNB1 Foundation | 12 | 2025-11-01 | 2026-03-25 |
| Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease Busulfan, Tocilizumab, Eltrombopag - Chronic Granulomatous Disease (CGD) | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Allergy and Infectious Diseases (NIAID) | 10 | 2025-09-10 | 2026-09-08 |
| A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation lamivudine, rapamycin, Exercise Regimen - Smokers, Former Smokers | Phase 1 | Active not recruiting | Icahn School of Medicine at Mount Sinai | 20 | 2025-08-12 | 2026-08-27 |
| Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study Base-edited hematopoietic stem and progenitor cells, Alemtuzumab, Sirolimus - CD40L-HyperIgM Syndrome | Phase 1 / Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 1 | 2025-07-16 | 2026-07-31 |
Showing 20 of 249. Sign in to see all of them.
Graft vs Host Disease (21) · Multiple Myeloma (19) · Myelodysplastic Syndromes (14) · Lymphoma (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Hematologic Neoplasms (12) · Leukemia (12) · Lymphoma, Non-Hodgkin (12) · Anemia, Sickle Cell (11) · Carcinoma, Non-Small-Cell Lung (11) · Hodgkin Disease (11) · Leukemia, Myeloid, Acute (10) · Prostatic Neoplasms (10) · Breast Neoplasms (9) · Glioblastoma (9)
National Cancer Institute (NCI) (37) · National Institute of Allergy and Infectious Diseases (NIAID) (12) · M.D. Anderson Cancer Center (11) · Mayo Clinic (9) · City of Hope Medical Center (7) · University of Chicago (7) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (5) · National Eye Institute (NEI) (5) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Roswell Park Cancer Institute (5) · H. Lee Moffitt Cancer Center and Research Institute (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Yale University (4) · Children's Hospital of Philadelphia (3) · Emory University (3)
United States (201) · China (12) · Canada (10) · Spain (5) · Australia (3) · France (3) · Italy (3) · Germany (2) · India (2) · Netherlands (2) · Sweden (2) · Israel (1) · Japan (1) · Russia (1) · Singapore (1)
Christopher G Kanakry, M.D. (5) · Elizabeth M Kang, M.D. (5) · Ezra Cohen, MD (3) · Filip Janku, MD, PHD (3) · Kunle Odunsi (3) · Luke Walker, MD (3) · Ai-Ling Lin, PhD (2) · Amit Oza (2) · Courtney F Joseph, M.D. (2) · Haris Ali (2) · John F Tisdale, M.D. (2) · Jose-Antonio Perez-Simon, MD-PhD (2) · Mandeep Singh, MD (2) · Robert Montgomery (2)
PMID 36240296, PMID 42133908, PMID 40132910, PMID 41871072, PMID 10028970, PMID 10030657, PMID 10199738, PMID 10213344, PMID 10556226, PMID 10594802, PMID 10598732, PMID 10802712, PMID 10830164, PMID 10952828, PMID 11055975, PMID 11057898, PMID 11250334, PMID 11514367, PMID 11803349, PMID 12088775, PMID 12555153, PMID 12652219, PMID 12668503, PMID 12714020, PMID 12738602, PMID 12742978, PMID 12906982, PMID 12962864, PMID 1423934, PMID 14612424, PMID 14757690, PMID 14996650, PMID 15226426, PMID 15239621, PMID 15302787, PMID 15543153, PMID 15557389, PMID 16030064, PMID 16199143, PMID 16297769, PMID 16297770, PMID 16297806, PMID 16364861, PMID 16611334, PMID 16614412, PMID 16642009, PMID 16795076, PMID 16873412, PMID 16896165, PMID 17060862
P30CA016672 (5), P30CA008748 (3), P30CA015083 (3), U01CA069856 (3), U01CA097452 (3), U10CA025224 (3), 2009 (2), 2025 (2), N01CM00071 (2), N01CM62201 (2), P30CA006973 (2), P30CA015704 (2), P30CA016056 (2), P30CA033572 (2), P30CA069533 (2)